New semisynthetic vinca alkaloids: chemical, biochemical and cellular studies by Orosz, F et al.
The numerous antimitotic drugs already developed and therapeu-
tically used for a large number of pathologies belong to different
classes based on their chemical structure and other distinctive
features. Antimitotic drugs usually target the tubulin/microtubule
network of the cytoskeleton that is formed by assembly of cyto-
plasmic tubulin dimers. The stability of the different microtubular
structures varies considerably; some of their functions depend on
their lability. The lability is augmented by the extreme sensitivity
to various drugs. Several synthetic and natural compounds interact
specifically with tubulin and/or microtubule, fundamentally
destroying its dynamic character and leading to cell death. A large
number of these agents are plant derived (Lin et al, 1988).
Vinca alkaloids, vinblastine and vincristine are potent anti-
mitotic agents, they have been effectively used in the cancer
therapy (Dustin, 1984). Because of their extensive clinical use, it
is important to synthesize additional agents having at least the
same biological activity. Numerous semisynthetic derivatives of
vinca alkaloids have been synthesized (Eli Lilly, Indianapolis, IN,
USA), however only few data for tubulin binding are available.
The chemical conversion of indols occurring in relatively large
amounts in the plant extract into potent semisynthetic anti-tumour
agents is also motivated by, on one hand, the extensive need for
potent anti-tumour agents in clinical chemotherapy and, on the
other hand, by the fact that the known drugs, vinblastine and
vincristine, have undesired side-effects.
Although it has been suggested that the primary target of the
bis-indol alkaloids is the microtubular network, they also bind to
calmodulin, a ubiquitous Ca2+ receptor protein that is involved in
the cell proliferation (De Brabander et al, 1980) and a number of
other physiological processes. Recently, we demonstrated that
the bis-indol vinca alkaloids display significant anti-calmodulin
activity (Molnár et al, 1995). The affinity of these drugs to tubulin
(Liliom et al, 1995) and calmodulin (Molnár et al, 1995) in in vitro
binding tests were found to be comparable. Nevertheless, it is
unclear yet how the anti-calmodulin activity of these drugs is
related to their desired and undesired pharmacological effects.
Recently, we reported (Orosz et al, 1997a,b) that a new bis-
indol derivative, KAR-2 [3¢-(b-chloroethyl)-2¢,4¢-dioxo-3,5¢-spiro-
oxazolidino-4-deacetoxy-vinblastine], with antimitotic activity
interacts with tubulin as well as with calmodulin in in vitro
systems. Electron microscopic studies on Chinese hamster ovary
cell lines revealed that KAR-2 targets microtubular network
destroying the cytoplasmic microtubular system. KAR-2 was
found to be a powerful anti-tumour agent on mouse leukaemia
P388 in vivo tests, however its administration did not induce
neurotoxic side-effects (e.g. paralysis of bladder or lower extremi-
ties) as observed in the case of bis-indols routinely used in therapy.
Moreover, we found that it was effective even in a single high
dose, whereas vincristine using the same administration schedule
was toxic or less effective than KAR-2 (Orosz et al, 1997a).
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KAR-2 was found to bind to calmodulin, however, in contrast to
other biologically active bis-indols used in cancer chemotherapy, it
did not show anti-calmodulin activity. Therefore, the binding does
not necessarily cause anti-calmodulin activity, in spite of the fact
that the binding affinities of the bis-indol derivatives examined to
calmodulin are comparable. It was suggested that this unique char-
acter of KAR-2 could be one of the reasons of its low toxicity
(Orosz et al, 1997a,b). To investigate whether the lack of anti-
calmodulin potency resides only on the spiro-oxazolidino portion
of KAR-2 and the modest chemical modification of bis-indol
structure is responsible also for the different pharmacological
effects, new derivatives have been synthesized for comparative
studies.
In this paper, the synthesis and structural elucidation of KAR-2
and two further new bis-indol derivatives, KAR-3 and KAR-4
(Figure 1), is described which are analogues of vincristine and
vinblastine respectively. These compounds were found to be
powerful anti-tumour agents on mouse leukaemia P388 and
Ehrlich ascites carcinoma in vivo tests and on neuroblastoma cell
lines. Biochemical studies showed that they effectively impeded
tubulin polymerization and specifically damaged single micro-
tubules but not the bundled ones. KAR-3 displayed significantly
higher anti-calmodulin and slightly higher anti-tubulin activity
than the other two KAR derivatives.
MATERIALS AND METHODS
General methods
Chemicals
Indol alkaloids vinblastine and vincristine were isolated from
Catharanthus roseus by the standard procedure carried out by
Chemical Works of Gedeon Richter, Hungary. 4-Deacetoxy-
vinblastine was isolated from Catharanthus roseus extract
according to De Bruyn et al (1982). 4-Deacetoxy-vincristine was
produced in acetone-methylene chloride from 4-deacetoxy-
vinblastine using n-Bu4NMnO4 as oxidizing agent. Taxol, GTP
and trifluoperazine were purchased from Sigma. All organic
reagents for synthesis of the new compounds were obtained from
Aldrich and were of the highest grade. All other chemicals were
reagent grade commercial preparations.
Proteins
Tubulin was prepared from calf brain using the Weisenberg
method modified by Na and Timasheff (1986). Purified tubulin
was virtually free from microtubule-associated protein bands
when run on overloaded sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE). Tubulin was stored in 1 M
sucrose, 10 mM sodium phosphate buffer, 0.5 mM magnesium
chloride and 0.1 mM GTP, pH 7.0, at –80°C and dialysed against
the appropriate buffer before use.
Calmodulin from bovine brain was purified to homogeneity
using Phenyl-Sepharose (Pharmacia) chromatography (Gopala-
krishna and Anderson, 1982). Its activity was checked by the phos-
phodiesterase test (Solti et al, 1983), or by phosphofructokinase
[ATP: D-fructose 6-phosphate 1-phospho-transferase, EC 2.7.1.11]
(PFK) test (Orosz et al, 1988).
PFK, aldolase and glycerol-3-phosphate dehydrogenase-
triosephosphate isomerase purified from rabbit skeletal muscle
were purchased in ammonium sulphate suspensions from Sigma or
Boehringer. The enzyme suspensions were centrifuged at 10 000g
for 5 min. The pellets were suspended in the appropriate buffer,
then the enzymes were gel filtered or dialysed in the same buffer to
remove ammonium sulphate.
Protein concentrations were determined spectrophotometrically,
using molar absorption coefficients of 1.06 ´ 105 M–1 cm–1 at
280 nm for tubulin (Na and Timasheff, 1986), 3.24 ´ 103 M–1 cm–1
at 276 nm for calmodulin (Watterson et al, 1976), 8.88 ´104 M–1 cm–1
at 280 nm for PFK (Hesterberg and Lee, 1982). Spectroscopic
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Figure 1 Scheme of synthesis of KAR derivatives
Compound (I) Compound (II) R1 R2
4-Deacetoxy-vinblastine KAR-2 CH3 CH2CH2Cl
4-Deacetoxy-vincristine KAR-3 CHO CH2CH2Cl
4-Deacetoxy-vinblastine KAR-4 CH3 CH2CH=CH21358 F Orosz et al
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measurements were made on HP 8451A or JASCO V-550 spectro-
photometers. Protein purity was determined by SDS-PAGE, as
described by Laemmli (1970)
Synthetic chemistry
Synthesis of KAR-2
[3¢-(b-chloroethyl)-2¢,4¢-dioxo-3,5¢-spiro-oxazolidino-4-deace-
toxy-vinblastine] (Figure 1B; R1, CH3; R2, CH2CH2Cl). Ten grams
(13.28 mmol) 4-deacetoxy-vinblastine (Figure 1A; R1, CH3) was
dissolved in 100 ml absolute tetrahydrofurane followed by the
addition of 8.0 ml (10.1 g; 95.9 mmol) chloroethyl-isocyanate.
After 2 h incubation at room temperature, 200 ml dried toluene
was added to the reaction mixture. Then the mixture was kept at
80°C for 18 h, cooled to 2°C and 40 ml water and 2 ml 25%
ammonia was added. The mixture was stirred for 30 min. After
separation of the organic phase, it was washed with water (3 ´ 30
ml) and dried with potassium sulphate and evaporated on a water
bath of 35–40°C at 20–27 hPa. The resulting material was
chromatographed on silica gel (500 g, bead size of 0.040–
0.063 mm) column (30 mm ´ 500 mm) using ethyl acetate/ethanol
(9:1) mixture as eluent. The yield was 3.29 g (30%).
KAR-2: thin layer chromatography: Rf= 0.70–0.75 (9:1 ethyl
acetate/ethanol); IR umax (potassium bromide): 3465, 1814, 1743,
1617, 1408, 1241, 1039, 741 cm–1; MS-FAB m/z 826 [M + H]+.
Sulphate salt: 3 g (3.63 mmol) pure base was dissolved in 5 ml
ethanol to which 7 ml ethanol containing 0.363 g (3.63 mmol)
sulphuric acid was added. The mixture was kept for 4 h at room
temperature and then evaporated on a water bath at 40°C under a
vacuum of 80 hPa to a final volume of 5–6 ml. The salt was
precipitated from the mixture by adding 20 ml ether then filtered
and dried at maximum 30°C at 13 hPa for 8–15 h, resulting in
a white, crystalline powder. The yield was 3.05 g (83%);
m.p. > 300°C (decomposed). Optical rotation (1% solution in
water): [aD]0
25 = +3.3°; [aD]25
Hg 578 = +3.6°; [aD]25
Hg 546 = +4.5°;
[aD]25
Hg 436 = +12.9°; [aD]25
Hg 365 = +36.7°.
Synthesis of KAR-3
[3¢-(b-chloroethyl)-2¢,4¢-dioxo-3,5¢-spiro-oxazolidino-4-deace-
toxy-vincristine] (Figure 1B, R1, CHO; R2, CH2CH2Cl). The steps
of synthesis of KAR-3 are the same as that of KAR-2, but starting
from the required (10 g, 11.9 mmol) deacetoxy-vincristine (Figure
1A; R1, CHO). The yield was 29% and 86% for KAR-3 and KAR-
3 sulphate respectively.
KAR-3: IR umax (potassium bromide): 3445, 1817, 1744, 1617,
1595, 1411, 1230, 1028, 742 cm–1; MS-FAB m/z 840 [M + H]+.
KAR-3 sulphate: m.p.> 300°C (decomposed); optical rotation
(1% solution in water): [aD]0
25 = +0.8°; [aD]25
Hg 578 = +1.0°;
[aD]25
Hg 546 = +1.2°; [aD]25
Hg 436 = +5.8°; [aD]25
Hg 365 = +25.9°.
Synthesis of KAR-4 [3¢-allyl-2¢,4¢-dioxo-3,5¢-spiro-oxazolidino-
4-deacetoxy-vinblastine] (Figure 1B; R1, CH3; R2, CH2CH=CH2).
The steps of synthesis of KAR-4 are the same as that of KAR-2,
but allyl isocyanate (10 ml, 9.4 g, 113.25 mmol) was used instead
of chloroethyl-isocyanate. The yield was 25% and 88% for KAR-4
and KAR-4 sulphate, respectively.
KAR-4: IR umax (potassium bromide): 3467, 1813, 1743, 1617,
1402, 1240, 1129, 1036, 741 cm–1; MS-FAB m/z 804 [M + H]+.
KAR-4 sulphate: m.p. > 300°C (decomposed); optical rotation
(1% solution in water): [aD]025 = +1.1°; [aD]25
Hg 578 = +1.4°;
[aD]25
Hg 546 = +1.8°; [aD]25
Hg 436 = +7.3°; [aD]25
Hg 365 = +30.8°.
Analytical methods
Reaction progress and purity were monitored by analytical thin-
layer chromatography on strips of Merck 3552 plastic-backed
silicon dioxide. Developed strips were viewed under light of 254
and 365 nm wavelengths. NMR measurements were carried
out on a Varian Unity plus-500 instrument (500 MHz for 1H and
125 MHz for 13C) in DMSO. Chemical shifts were determined
relative to dTMS = 0.00 p.p.m. 1H and 13C signal assignments
were verified by a concerted use of two-dimensional 1H–1H and
1H–13C shift correlation methods (DQFCOSY, HSQC, HMBC) and
NOESY experiments. The gradient-enhanced DQFCOSY, HSQC,
HMBC and NOESY experiments were recorded by using the
standard spectrometer software package. A mixing time of
tmix = 0.5 s was used for the NOESY experiments. An IR spectrum
was obtained from potassium bromide pellets on a Nicolet-20 DxC
FT-IR spectrometer and was consistent with the assigned structure.
Melting point (m.p.) was taken on an Electrothermal digital m.p.
apparatus (IA 8103) and is uncorrected. Mass spectrum was
recorded on a Kratos MS 80 instrument using FAB.
In vivo anti-tumour effects in P388 sensitive and
resistant leukaemias
Mouse leukaemia P388 cells were maintained on DBA/2 inbred
mice and transplanted by the intraperitoneal (i.p.) route to groups
consisting of six BDF1 hybrid mice each. A dose of 106 tumour
cells per animal each was administered (five or six mice per
group). For antitumoral studies, the drugs were dissolved in
physiological saline and the solutions were administeredd using
single doses i.p. during the 24th h after transplantation. The body
weight and condition of the animals were registered daily. The
effect achieved on the treated animals, i.e. the anti-tumour activity,
was expressed as percentage of the life span related to the average
life span (in days) of the control group [T/C(%)]:
T/C(%) = median day of survival of treated animals ´ 100
median day of survival of control animals
In vivo anti-tumour effects in Ehrlich ascites carcinoma
Mouse Ehrlich ascites tumour cells were maintained on
C57BL/65co mice and transplanted by i.p. route to groups
consisting of three C57BL/65co mice each. The animals were
8 weeks old, weighing over 30 g and they were housed in a
climate-controlled pathogen-limited environment with standard
rodent feed and clean water ad libitum. Animals before tumour
implantation were selected using a random number chart without
regard to treatment group assignment. A dose of 2 ´ 107-tumour
cells per animal (100 ml) i.p. was injected. The cell concentration
and viability were checked before and after the tumour administra-
tion. For anti-tumour studies, newly synthesized and reference
drugs were dissolved in Dulbecco’s phosphate-buffered saline
(Sigma), and the solution was administered i.p. using a single dose
4 days after transplantation. The body weight and condition of the
animals were registered daily. The animals were sacrificed
8 days after injection of tumour and 4 days after the administration
of drugs. Tumour volume was measured using a calibrated
syringe. Also, tumour cell number was counted using a Coulter
Multisizer II AccuComp (Coulter Corporation) and flow cytom-
etry with propidium iodide 18 mg ml–1. Viability was also checked
by the latter method. Propidium iodide excitation was obtainedwith an argon ion laser adjusted to deliver 15 mW at 488 nm, and
fluorescence was detected using a 675-nm band-pass filter.
Microculture tetrazolium assay (MTA)
Human neuroblastoma cell line (SH-SY5Y) was cultured in 75 cm2
flask with NCTC-135 medium (Sigma) + 1% antibiotic + 10%
fetal bovine serum. Cells were trypsinized, counted by trypan blue
exclusion and dispersed within replicate 24-well culture plates
(1 ml per well and 75 000 cells ml–1) in 100 ml volumes containing
the same medium but only supplemented with 2% fetal bovine
serum. After a 24 h incubation at 37°C, 5% carbon dioxide, 100%
relative humidity in Heraeus Forma Scientific 3862 incubator,
KAR derivatives were inoculated at various concentrations
(control group, n = 12; each drug treatment group, n = 4).
Medium/tetrazolium reagent blank (n = 4) was utilized for ‘back-
ground’ determination. Culture plates were then incubated at 37°C
for 4 days before the addition of tetrazolium reagent. Forty
microlitres of 50 mg ml–1 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was added to each culture
well (resulting in 0.2 mg ml–1 final concentration) and cultures
were incubated at 37°C for 24 h. MTT-formazan is generated by
cellular reduction of the MTT tetrazolium reagent. Assuming that
cellular reductive activity is constitutive and remains relatively
constant throughout the duration of an experiment, the viable cell
number is directly proportional to the production of formazan,
which was measured after solubilization (Finlay et al, 1986). After
incubation, cell monolayers and formazan were inspected micro-
scopically. Then the culture medium supernatants were removed
from wells by slow aspiration (needle suction) and replaced with
500 ml DMSO. After formazan solubilization (vibration on a plate
shaker), the absorbance of each well was measured spectrophoto-
metrically at 540 nm. Cell line growth and growth inhibition were
expressed in terms of mean (± s.d.) absorbance units and/or
percentage of control absorbance (± s.d.) after subtraction of mean
‘background’ absorbance.
Electron microscopy
Samples for electron microscopy were prepared by incubating
10 mM tubulin, 20 mM taxol, 2 mM PFK without and with drugs
(2 mM) for 30 min at 30°C. For negative staining, a drop from the
unpelleted samples was applied to formvar/carbon-coated glow-
discharged copper grids for 30 s. The solution was removed and
the grid stained with one drop of freshly filtered 1% aqueous
uranyl acetate for 30 s. The excess of stain was removed by blot-
ting with filter paper. The specimens were examined and
photographed in a Jeol CX 100 electron microscope operated at an
accelerating voltage of 80 kV. Magnification was calibrated with a
diffraction grating replica (2160 l mm–1, Balzers).
Turbidity measurements
Tubulin was incubated in the presence and absence of drugs at
different concentrations in 50 mM MES buffer at pH 6.8
containing 100 mM, potassium chloride, 5 mM magnesium chlo-
ride, 2 mM dithioerythritol at 37°C. The drugs were added to the
thermostated solution in the cuvette. The assembly was started
with the addition of taxol to the samples in a final concentration of
20 mM from 10 mM stock solution in DMSO. Change of absorbance
was monitored at 350 nm by a Hewlett Packard 8451A spectro-
photometer. The effects of drugs were determined from the initial
rates of the polymerization curves measured at different drug
concentrations. The IC50 values of the drugs were calculated from
the dose–response curves with the method of maximum likelihood
probit analysis.
Pelleting experiments
Tubulin polymerization was carried out in 50 mM Hepes, 100 mM
potassium chloride, 5 mM magnesium chloride at pH 7.0, at
30°C with 10 mM tubulin. For vinblastine or KAR-2-treated
samples, tubulin was preincubated with 2 mM drug in the absence
and presence of 2 mM PFK. The assembly was started by addition
of taxol to the samples in a final concentration of 20 mM. Then the
samples were centrifuged at 100 000 g for 20 min at 30°C. Under
these conditions, microtubules and microtubule-bound PFK are
completely pelleted, whereas non-microtubule-bound (uncom-
plexed) PFK and non-polymerized tubulin dimers remain in the
supernatant (Lehotzky et al, 1993, 1994; Vértessy et al, 1996).
The protein amount in the pellet and supernatant fractions was
quantified by densitometry after SDS-PAGE separation in 9%
polyacrylamide gels using the BioRad GelDoc 1000 densitometer
with the Molecular Analyst software (Vértessy et al, 1996, 1997).
Anti-calmodulin activity assay
PFK (6 mg ml–1) was extensively dialysed against 0.1 M potassium
phosphate buffer, pH 8.0, containing 5 mM dithioerythritol to
remove ammonium sulphate. For preincubation of PFK with
calmodulin and drugs, the enzyme was diluted to 1.2 mM protomer
concentration into Hepes buffer containing 100 mM potassium
chloride, 10 mM magnesium chloride, 10 mM disodium hydrogen
phosphate and 100 mM calcium chloride. The final concentrations
of calmodulin and drugs were 3 mM and 20 mM respectively. After
60 min, 10-ml aliquots were withdrawn to assay PFK activity in
1 ml at 37°C in 50 mM Tris, pH 8.0, containing 2 mM fructose-
6-phosphate, 1 mM ATP, 3 mM magnesium chloride, 0.2 mM
NADH, 3 mM dithioerythritol, 0.1 mM ethylene glycol bis(b-
aminoethylether)-N,N,N¢,N¢-tetraacetic acid, 2 units of aldolase,
12 units of triosephosphate isomerase, and 2 units of glycerol-3-
phosphate dehydrogenase (Mayr, 1987; Lehotzky et al, 1993). The
reaction was followed by NADH consumption at 340 nm using
Simadzu spectrophotometer. The specific activity of PFK was
159 U mg–1 measured at 1 mgm l –1 final concentration after dilu-
tion from 1 mg ml–1 stock solution into activity assay.
RESULTS
Structural characterization of the synthesized KAR
derivatives
KAR-2 was readily synthesized from 4-deacetoxy-vinblastine
occurring in significant amounts in Catharanthus roseus.
Substituents of the C3 atom of the vindoline moiety, COOCH3 and
OH, were cyclized into an oxazolidino ring using a bifunctional
reagent, b-chloroethyl-isocyanate. The synthesis of KAR-4 was
performed in a similar way using allyl isocyanate as reagent. For
synthesis of KAR-3, 4-deacetoxy-vincristine was used which
was obtained by oxidation of 4-deacetoxy-vinblastine using
n-Bu4NMnO4 as oxidation agent. In this way, the yields were only
New potent bis-indol derivatives   1359
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25–30% because of the side reactions, however the reactive
chloroethyl or allyl groups may serve as initial points of further
modifications. KAR-2, KAR-3 and KAR-4 were separated from
byproducts by silica gel chromatography. The sulphate salts were
prepared from the drugs dissolved in ethanol and sulphuric acid.
The structures of all the three KAR derivatives were verified by
high-field NMR measurements in the liquid phase. 1H-NMR and
13C-NMR data are consistent with the structures of Figure 1*. We
note that all three bis-indols exhibit complex internal dynamics. In
particular, the flexibility of the nine-member ring gives much
motional degree of freedom to the system. In addition, rotation
about the C(18¢)–C(15) bond gives further conformational species.
In each molecule, the NMR spectra exhibit conspicuously broad
resonances, which indicates that at least one of these internal
motions is moderately slow on the chemical shift time scale. The
pronounced exchange broadening persisted even at elevated
temperatures (45°C for KAR-2 and at 49°C for KAR-3 and KAR-
4), which led to a masking of the 1H–1H coupling patterns and the
extreme widening of some C–H proton and carbon resonances. For
example, the proton signals due to C(3)H2, C(5)H2 and C(21)H
could only be identified through the 2D 13C–1H correlation experi-
ments. Nevertheless, the combined use of COSY, HSQC and
HMBC and NOESY measurements proved to be successful in
establishing the 1H–1H and 1H–13C scalar and dipolar networks in
the molecules.
In vivo anti-tumour potency on P388 mouse ascites
leukaemia
Previously, we demonstrated that KAR-2 displays significant anti-
tumour potency on P388 mouse leukaemia (Orosz et al, 1997a).
Both KAR-3 and KAR-4 have a very similar dose-dependent
effect on this tumour to KAR-2. Based on the possibility of admin-
istering high doses as observed during the experiments, the tests
were carried out by using single doses. This administrational
schedule revealed that KAR derivatives were effective in a single
i.p. dose of 20 mg kg–1. Their maximal effects were about
200 T/C(%). This value was reached using 20 mg kg–1, 40 mg kg–1
and 60 mg kg–1 for KAR-3, KAR-4 and KAR-2 respectively
(Table 1). The maximal tolerated dose were extremely high
for KAR-2 (80 mg kg–1), even in comparison to the other KAR
derivatives.
In vivo anti-tumour potency on Ehrlich ascites
carcinoma
A very important factor for testing the anti-tumour ability of a
novel compound is its preserved activity when treatment is
delayed after the graft, i.e. a preserved efficiency of this drug when
the tumour is sufficiently expanded which better mimicked the
clinical reality. For this purpose, KAR derivatives (40 mg kg–1)
were applied for treatments to compare the anti-tumour potencies
of the new compounds in the Ehrlich carcinoma test. As shown in
Table 2A, each of the KAR derivatives display a significant effect
on the tumour cell proliferation, however KAR-2 and KAR-3
seem to be more effective in decreasing the cell number than
Table 1 Effect of drugs in various tests
In vivo effect Cytotoxicity Anti-tubulin effect Anti-calmodulin activity
P388 MTA Turbidity Effect on calmodulin
(single doses) at 350 nmc induced PFK inactivationd
Drug Maximal Dose IC50 (mM)I C 50 (nM) Activity Efficiency
effect (mg kg–1) (U mg–1) (%)
T/C (%a)
KAR-2 207 ± 24b 60b 0.31 ± 0.06 200 ± 79 11.1 ± 0.6 5
KAR-3 187 ± 40 20 0.31 ± 0.05 136 ± 61 34.4 ± 1.8 45
KAR-4 214 ± 21 40 0.35 ± 0.01 185 ± 83 10.9 ± 0.7 5
Vinblastine – – 0.005 ± 0.001 248 ± 42 – 61e
Vincristine 147 ± 36b 1b 0.013 ± 0.001 290 ± 79 – 62e
Trifluoperazine – – – – 46.1 ± 2.2 65
For experimental details see Materials and methods.
a T/C (%) =
median day of survival of treated animals
´ 100
median day of survival of control animals
Number of animals used: six per groups
b Data published also in Orosz et al (1997a). c Polymerization curves of tubulin were obtained by measuring turbidity (absorbance at 350
nm) in the absence and presence of drugs. Tubulin was used at 20 mM concentration. The data are the average of three independent
measurements. d Concentrations of PFK (in protomers), calmodulin and drugs were 1.2 mM, 3 mM and 20 mM respectively. Residual
activity of PFK after 60 min incubation in the absence and presence of calmodulin was 66.6 U mg–1 (100%) and 8.0 U mg–1 (0%)
respectively. Efficiency was calculated from the activity data by the following formula:
Efficiency =
ActivityPFK–CaM–drug – ActivityPFK–CaM
ActivityPFK – Activity PFK–CaM
e Data taken from Molnár et al (1995).
*1H and 13C chemical shift data for the sulphuric acid salts of compounds KAR-2,
KAR-3 and KAR-4 will be published elsewhere.New potent bis-indol derivatives   1361
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KAR-4. Because KAR-3 showed lower T/C(%) at single dose
administration in P388 test (Table 1) than KAR-2, the latter
compound was further investigated and its efficiency was
compared with that of the clinically relevant vincristine in a dose-
dependent way (Table 2B). The KAR-2 and vincristine doses used
for treatments were varied in different ranges to be effective but
not toxic. KAR-2 and vincristine inhibited tumour cell prolifera-
tion in all the doses used. Significant decrease of the tumour cell
density can be observed in the cases of both drug treatments as a
function of concentration. As shown in Table 2B, the total cell
numbers reached the lowest values when the animals were treated
with 40 mg KAR-2 kg–1 mouse (24% of the control). In contrast,
the maximum dose of vincristine that did not result in the death of
the animals (10 mg vincristine kg–1 mouse) decreased the total cell
number to only 45% of the control value. The cell viability
appeared to be well maintained (over 98%) after the treatments.
The treated animals showed consistent body weight patterns as
well as eating and drinking habits with the controls during the
experiments. This finding shows that at the selected doses the
treatments were well tolerated by the mice, except at the highest
dose of vincristine which caused the death of two of the three
treated animals. It can be, therefore, concluded from these in vivo
experiments that KAR-2 is more effective in inhibiting tumour cell
proliferation than vincristine.
Cytotoxicity of KAR derivatives in neuroblastoma cells
The cytotoxicity on human neuronal tumour cells caused by KAR
derivatives was quantified by a MTA involving DMSO solubiliza-
tion of MTT-formazan (Alley et al, 1988). We used this approach
to discriminate between viable and unviable cell groups in KAR
derivative-treated neuroblastoma cell culture. The drugs were
added to neuroblastoma cells in various concentrations, and after
4-day treatments the viable cells were quantified by MTA. As
shown in Table 1, the growth inhibitory concentration range
observed with KAR derivatives was about 0.3 mM IC50. This value
was significantly lower for vincristine and vinblastine (IC50 =
13 nM and 5 nM, respectively).
Table 2 In vivo antitumour effects on Ehrlich ascites carcinoma after treatment with single dose of drugs
Table A
Drug Dose Volume of tumour Cells ml–1 Total cells
(mg kg–1) per mouse (ml) (per cent of control)a (per cent of control)a
Initial valueb 1.33 10 ± 3 3.2 ± 3
Control 5.33 100 ± 4 100 ± 4
KAR-2 40 2.33 56 ± 62 4 ± 6
KAR-3 40 3.00 57 ± 83 2 ± 8
KAR-4 40 3.33 90 ± 14 57 ± 14
Table B
Drug Dose Volume of tumour Cells ml-1 Total cells
(mg kg–1) per mouse (ml) (per cent of control)a (per cent of control)a
Control 2.67 100 ± 2 100 ± 2
Vincristine 1 2.00 157 ± 2 57 ± 2
2 1.50 106 ± 2 60 ± 2
5 0.64 225 ± 2 54 ± 2
10 0.53 224 ± 2 45 ± 2
15c –– –
KAR-2 20 1.97 63 ± 2 46 ± 2
40 1.17 60 ± 6 24 ± 6
60 1.70 46 ± 2 29 ± 2
80d 0.45 211 ± 2 36 ± 2
Mouse Ehrlich ascites tumour cells were maintained on C57BL/65co mice and transplanted by i.p. route. Drugs were
administered i.p. 4 days after tumour implantation. The animals (three per group) were sacrificed 8 days after
implantation of the tumour (4 days after administration of drugs). For other details see Materials and methods.
aTumour cell numbers from treated mice are expressed as percentage of the control:tumour-treated mice without
drug administration sacrificed 8 days after implantation of the tumour.
A: 100% equals 1240 ±4% ´ 106 cells ml–1 and 6769±4% ´ 106 total cell number.
B: 100% equals 275 ±1.4% ´ 106 cells ml–1 and 734±1.4% ´ 106 total cell number.
bDetermined 4 days after tumour implantation, before the administration of the drugs. cThe animals died before the
sacrifice.dThe animals were dying in the same day of the sacrifice.1362 F Orosz et al
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Antimicrotubular activity
Because KAR derivatives were found to be effective in anti-
tumour tests in vivo, we compared their antimicrotubular activities
in vitro in a tubulin assembly system. The polymerization was
induced by taxol and visualized by turbidimetry (Schiff et al,
1979). The half-maximum inhibitions (IC50) occurred between
100 and 200 nM for KAR derivatives and between 250 and
300 nM for vinblastine and vincristine (Table 1). The inhibitory
effect of KAR-3 is slightly higher than that of the other two
KAR derivatives.
Selectivity of antimicrotubular activity
To assess whether the effect of the KAR derivatives depends on
the organization state of the tubulin/microtubule system, the
PFK-induced bundling (cross-linking) process was analysed in the
presence and absence of the drugs. The bundling activity of PFK
was previously demonstrated in vitro (Lehotzky et al, 1994).
The concentration of drugs (2 mM) was selected to inhibit signifi-
cantly the tubulin polymerization in the absence of PFK (cf. the
IC50 values in Table 1) (Figure 2, curves A and B). When tubulin
assembly was monitored by turbidity measurements in the pres-
ence of KAR-2 and PFK, we observed that the turbidity is exten-
sively increased, suggesting that PFK can overcome the inhibitory
effect of KAR-2 on tubulin polymerization (Figure 2, curves C
and D). The effects of KAR-3 and KAR-4 on tubulin polymeriza-
tion were similar to that of KAR-2, both in the absence and
presence of PFK (data not shown). These results are similar to
those obtained with vinblastine (Lehotzky et al, 1994), however
the resistance of bundled microtubules was higher when KAR-
derivatives were used.
The results of pelleting experiments are consistent with the
turbidity measurements. To detect the alteration in the microtubule
formation caused by the drugs, the centrifugation speed was
chosen such that single and PFK-bundled microtubules were
pelleted while tubulin dimers or small oligomers were in the
supernatant. Therefore, the partition of tubulin in the pellets and
the supernatants is indicative to the effect of drugs expressed
on the single and bundled microtubules. Figure 3 shows the gel
electrophoresis pictures of the pellets and supernatants of the
untreated, KAR-2- or vinblastine-treated tubulin samples. The
double bands are characteristic of the a and b subunits of tubulin
dimers. In the absence of drugs with and without PFK, tubulin can
be visualized only in the pellet, indicating that all tubulins were
assembled into the microtubule under the experimental conditions
used. In the PFK-containing sample, an additional band appears,
the position of which corresponds to the molecular mass of the
PFK subunit. If the assembly was carried out in the presence of
drugs but without PFK, practically all tubulin appears in the super-
natants showing that both drugs prevented the microtubule forma-
tion. When the tubulin polymerization was carried out with PFK,
significant amount of tubulins were assembled into microtubules
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Figure 2 Polymerization curves of 10 mM tubulin obtained by measuring
turbidity in the absence (A) and (B) and presence (C) and (D) of 2 mM PFK.
Tubulin was polymerized under conditions as described in Materials and
methods. Turbidity was measured at 350 nm in the absence (B) and (D) and
in the presence (A) and (C) of 2 mM KAR-2
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Figure 3 Dependence of drug effects on microtubule ultrastructure: SDS-
PAGE of drug-treated samples. Single and bundled microtubules were
prepared in the absence and presence of PFK, respectively, as described in
Materials and methods. Supernatants (S) and pellets (P) of untreated and
vinblastine- or KAR-2-treated samples were assayed in SDS-PAGE.
Samples are: 1, control; 2, plus PFK; 3, plus PFK and vinblastine; 4, plus
PFK and KAR-2; 5, plus vinblastine; 6, plus KAR-2. (A) PFK; (B) tubulin a
and b subunits
A BCD
Figure 4 Electron micrographs of tubulin samples containing vinblastine (A), vinblastine plus PFK (B), KAR-2 (C), and KAR-2 plus PFK (D) prepared and
stained as described in the Materials and methods. Microtubules are present in B and D; they are, however, absent in A and C. All of the samples contain
numerous C-shaped and thread-like oligomers. Bars, 60 nmeven in the presence of vinblastine, and virtually no depolymer-
izing effect of KAR-2 can be observed. This finding provides
evidence that the antimicrotubular activity of KAR-2 is highly
dependent on the ultrastructure of microtubules.
Electron microscopic examination of the tubulin polymer
formed in the simultaneous presence of drugs (2 mM) and PFK
(2 mM) supports these conclusions. As shown in Figure 4,
numerous short microtubules are seen in samples containing
tubulin-PFK and drug (vinblastine or KAR-2), however they are
absent in samples prepared without addition of PFK. Similar
results were obtained with KAR-3 and KAR-4 (data not shown).
A common feature of the samples is that they contain many
C-shaped aggregates that probably represent tubulin ligomers.
However, no such profiles were seen in samples assembled in the
presence of PFK without addition of drugs (Lehotzky et al, 1994).
Anti-calmodulin activities
Ca2+-calmodulin-modulated PFK activity is a well-established
system to test anti-calmodulin activity of drugs (Orosz et al, 1988,
1990). The affinity of drugs and PFK to calmodulin is comparable,
which renders it possible to use relatively low drug concentrations
and thus the direct binding of drugs to PFK can be disregarded
(Orosz et al, 1988). In addition, our previous data suggested that
the inhibitory potency of drugs suppressing the modulating effect
of calmodulin manifested itself in both phosphodiesterase and
PFK systems in a similar manner (Orosz et al, 1990).
To compare the anti-calmodulin activities of KAR derivatives,
KAR-2, KAR-3 and KAR-4, their effects on the calmodulin-stim-
ulated inactivation of PFK was measured. The experimental
system was adjusted to get, on one hand, a high degree of inhibi-
tion of PFK by calmodulin, and on the other hand a significant
amount of calmodulin to be complexed with PFK. PFK (1.2 mM) in
protomers was preincubated with and without Ca2+-calmodulin in
the absence and presence of drugs. KAR derivatives as well as
trifluoperazine, a classic calmodulin antagonist, as a reference
molecule were added at 20 mM final concentrations. After 60 min
incubation, the samples were assayed for PFK activity. The results
are summarized in Table 1. According to expectation (Ovádi,
1989), the inhibitory effect of calmodulin on PFK activity was
significantly attenuated by trifluoperazine, but not at all by KAR-2
(Orosz et al, 1997b). As shown in Table 1, KAR-4, similar to
KAR-2 (both are vinblastine derivatives), does not display anti-
calmodulin activity in the PFK assay, whereas KAR-3 can exten-
sively reduce the calmodulin-mediated inactivation of PFK by
about 50% suggesting its significant anti-calmodulin potency.
DISCUSSION
Bis-indol derivatives are among the most potent antimitotic agents
expressing their activities predominantly on tubulin/microtubule
system. Active derivatives, such as vinblastine and vincristine, are
isolated from plant extract. These drugs are extensively used in
chemotherapeutic treatments and they are very effective to arrest
mitosis of cells, however there are limitations in their clinical
administrations. One of the problems is the limited amount of
these drugs extracted from Catharanthus roseus. There are strate-
gies to produce new potent molecules by derivation of natural
molecules. We have synthesized novel compounds, KAR-2, KAR-
3 and KAR-4, which are semisynthetic derivatives of bis-indols
occurring in the Catharanthus roseus extract in relatively large
amounts. The KAR derivatives were synthesized from 4-deace-
toxy-vinblastine or 4-deacetoxy-vincristine. Substituents of the C3
atom of the vindoline moiety, COOCH3 and OH, were cyclized
into oxazolidino ring using bifunctional reagents (Figure 1). The
synthesis is a relatively simple process and it can not be fulfilled
by good efficiency (yields are between 25 and 30%), however the
reactive chloroethyl or allyl groups may serve as initial points of
further modifications.
These newly synthesized compounds differ chemically from
vinblastine and vincristine by the substitution of the 3 and 4 carbon
atoms of the vindoline moiety: the acetoxy group on the C4 atom
is replaced by H atom and it contains differently substituted oxazo-
lidino group on the C3 atom. Oxazolidino derivatives of
bis-indol alkaloids substituted by acetoxy and acetyl groups at
position C4 were synthesized by Eli Lilly (Miller and Antowsk,
1984) as well. However, those compounds investigated in binding
assays in vitro (Codaccioni et al, 1988) and on different tumours
(Lathan et al, 1985) were not found to be superior to vinblastine or
vincristine.
Turbidity measurements revealed that the KAR derivatives
displayed significant inhibitory effects on tubulin polymerization
in vitro. Obviously, the inhibition by drugs at a given drug concen-
tration is highly dependent on the system used as polymerization
assay. For example, in Hepes and glutamate systems, the
inhibitory effects of antimitotic drugs manifested themselves at
lower and higher drug concentrations, respectively, than in MES
buffer (Orosz et al, 1997a). Nevertheless, the tendency that KAR
derivatives, especially KAR-3, inhibit in vitro tubulin assembly at
lower drug concentrations than vinblastine and vincristine is clear.
In contrast, we found that if the polymerization was carried out
in the presence of a crosslinking protein, PFK, the microtubule
formation was much less inhibited by KAR derivatives than in the
absence of the bundling protein. This observation suggests that the
effect of bis-indols, including KAR-derivatives, on microtubule
assembly depends highly on the ultrastructural state of micro-
tubules, and the structural changes of KAR derivatives does not
cause a quantitative difference in this effect.
This exciting phenomenon may possess pharmacological rele-
vance. Depending on the cell type and cellular conditions, the
relative amounts of tubulin dimers, microtubules and bundled
microtubules vary in a wide range. For example, bundling of
microtubules can be induced by MAPs and other proteins (e.g.
PFK), or the ATP level modulates the enzyme-induced bundling of
tubules (Durrieu et al, 1987; Lehotzky et al, 1994). Our data
suggest that the bundled microtubules become resistant, at least
partially, to these antimitotic agents. In contrast, rapidly growing
tumour cells are characterized by a high rate of glycolysis with a
concomitantly high ATP level. Several mechanisms are respon-
sible for this property (Schneider, 1981). As we suggested recently
(Vértessy et al, 1997), one of the possibilities is that PFK is not
attached to microtubules at a relatively high MgATP level
(Lehotzky et al, 1994; Vértessy et al, 1997), therefore, in its
unbound form, it exhibits high overall activity ensuring high
glycolytic flux. At MgATP levels high enough to prevent PFK
binding to microtubules, kinase-induced cross-bridging of tubules
cannot occur, possibly rendering single tubules more sensitive to
bis-indol treatment than cross-bridged microtubules.
Mouse leukaemia P388, an in vivo tumour model, was suggested
as a reasonable prescreen because it is sensitive to most classes of
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overloading the panel (Cros et al, 1989; and references therein).
Our previous data showed that KAR-2 is an effective drug in this
test and its efficacy is similar to or slightly lower than those of
vincristine and vinblastine in repeat doses, although its effective
dose is higher. T/C values were 199% and 174% for vinblastine
(0.2 mg kg–1) and KAR-2 (1 mg kg–1), respectively, at eightfold
treatment (Orosz et al, 1997a). KAR-3 and KAR-4 behave simi-
larly to KAR-2 (data not shown). Although the effective doses of
KAR derivatives are higher than those of vinblastine/vincristine,
the disadvantage of the vinblastine/vincristine administration in
the chemotherapeutic treatments is that the prolonged treatments
are frequently not effective because of the multidrug resistance
problem. The administrational schedule revealed an advantageous
property of the KAR derivatives: they were active even in a single
high dose (Table 2), whereas single doses of vincristine were less
effective or caused the death of the animals. A similar observation
was noted in another type of experiment using mice hosting
Ehrlich ascites tumour cells, in which tumour was allowed to
develop for 4 days before drug administration. The fact that
significant prolongation of life span could be reached by a single
high, but not toxic, dose of the KAR derivatives makes them
potential candidates for further pharmacological and clinical
investigations. However, it remains to be tested whether these
drugs have the same characteristics in the clinical treatment.
Additionally, we have observed in experiments with a neuro-
blastoma cell line that KAR derivatives exhibit similar cytotoxicity,
but their IC50 values are significantly higher than that of vincristine
in spite of the fact that their antimicrotubular activities are in the
same order of magnitude.
Calmodulin as a key calcium receptor protein modulates
several very different cellular functions and metabolism.
Previously, we have reported that vinblastine, vincristine and
KAR-2 interact with calmodulin, their affinities are comparable
with that of tubulin and that their interaction is a Ca2+ dependent
process (Molnár et al, 1995; Orosz et al, 1997b). However, we
found that KAR-2 does not display anti-calmodulin activity in the
PFK assay (Orosz et al, 1997b). To investigate whether the lack of
anti-calmodulin potency resides only on the spiro-oxazolidino
portion of KAR-2, we tested the other KAR derivatives for anti-
calmodulin potency. KAR-2 and KAR-4 do not have calmodulin
antagonist effect in a calmodulin-modulated enzymatic test,
whereas KAR-3 can partially suspend the modulating effect of
calmodulin. Therefore, we conclude that the ‘extra’ ring of these
compounds is responsible for the decreased or diminished anti-
calmodulin activities; in contrast, the substitution of the methyl
group (KAR-2, KAR-4) by a formyl one (KAR-3) at a position
apart from the oxazolidino ring can selectively modify the anti-
calmodulin potency of KAR derivatives. Although we do not
have unambiguous evidence for the direct relationship between
anti-calmodulin potency and undesired toxic side-effects of
bis-indols, our data allow one to speculate about the relationship
of these effects.
ABBREVIATIONS
MES, 2-(N-morpholino)-ethanesulphonic acid; MTA, microcul-
ture tetrazolium assay; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; PFK, phosphofructokinase [ATP:
D-fructose 6-phosphate 1-phospho-transferase].
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